RBAK

Summary

RBAK (RB associated KRAB zinc finger, HGNC:17680) is a protein-coding gene on chromosome 7p22.1, encoding RB-associated KRAB zinc finger protein (Q9NYW8). May repress E2F-dependent transcription.

This gene encodes a nuclear protein which interacts with the tumor suppressor retinoblastoma 1. The two interacting proteins are thought to act as a transcriptional repressor for promoters which are activated by the E2F1 transcription factor. This protein contains a Kruppel-associated box (KRAB), which is a transcriptional repressor motif. Read-through transcripts that include exons from the downstream gene LOC389458 are expressed from this locus.

Source: NCBI Gene 57786 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 95 total — 1 likely-pathogenic
• MANE Select transcript: NM_021163

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17680
Approved symbol	RBAK
Name	RB associated KRAB zinc finger
Location	7p22.1
Locus type	gene with protein product
Status	Approved
Aliases	ZNF769
Ensembl gene	ENSG00000146587
Ensembl biotype	protein_coding
OMIM	608191
Entrez	57786

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 9 protein_coding, 1 retained_intron

ENST00000353796, ENST00000396912, ENST00000476992, ENST00000897998, ENST00000919280, ENST00000919281, ENST00000919282, ENST00000945090, ENST00000945091, ENST00000945092

RefSeq mRNA: 2 — MANE Select: NM_021163 NM_001204456, NM_021163

CCDS: CCDS5337

Canonical transcript exons

ENST00000396912 — 5 exons

Exon	Start	End
ENSE00001526717	5063695	5069487
ENSE00001526724	5045860	5046396
ENSE00003706484	5057684	5057779
ENSE00003888823	5057295	5057421
ENSE00003891902	5048033	5048091

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 95.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.3772 / max 55.3051, expressed in 1628 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
77084	5.3772	1628

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	95.02	gold quality
esophagus squamous epithelium	UBERON:0006920	94.41	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.86	gold quality
visceral pleura	UBERON:0002401	93.80	gold quality
parietal pleura	UBERON:0002400	93.63	gold quality
tibia	UBERON:0000979	92.51	gold quality
gingival epithelium	UBERON:0001949	92.29	gold quality
pancreatic ductal cell	CL:0002079	92.15	gold quality
endothelial cell	CL:0000115	91.45	gold quality
gingiva	UBERON:0001828	91.45	gold quality
palpebral conjunctiva	UBERON:0001812	90.86	gold quality
germinal epithelium of ovary	UBERON:0001304	90.76	gold quality
epithelium of nasopharynx	UBERON:0001951	90.55	gold quality
deltoid	UBERON:0001476	89.60	gold quality
oral cavity	UBERON:0000167	88.44	gold quality
tibialis anterior	UBERON:0001385	88.38	silver quality
caput epididymis	UBERON:0004358	87.88	gold quality
ileal mucosa	UBERON:0000331	87.64	gold quality
cauda epididymis	UBERON:0004360	87.44	gold quality
amniotic fluid	UBERON:0000173	87.03	gold quality
corpus epididymis	UBERON:0004359	86.95	gold quality
middle temporal gyrus	UBERON:0002771	86.79	gold quality
biceps brachii	UBERON:0001507	86.60	gold quality
pigmented layer of retina	UBERON:0001782	86.03	gold quality
vastus lateralis	UBERON:0001379	85.89	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	85.86	gold quality
cartilage tissue	UBERON:0002418	85.81	gold quality
bronchial epithelial cell	CL:0002328	85.65	gold quality
primary visual cortex	UBERON:0002436	85.57	gold quality
mucosa of sigmoid colon	UBERON:0004993	85.08	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-GEOD-100618	no	231.31
E-ANND-3	no	4.17

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
PMS2
ZNF226

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

171 targeting RBAK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-6508-5P	99.92	70.67	2465
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10523-5P	99.91	69.22	2038

Literature-anchored findings (GeneRIF, showing 6)

• Novel transcription factors identified in human CD34 antigen-positive hematopoietic stem cells. (PMID:12070015)
• RBaK interacts with the androgen receptor and increases its transcriptional activity. (PMID:14664718)
• study found no evidence of mutations in the coding sequence and splice sites of RBaK in association with familial hyperaldosteronism type II (PMID:17121540)
• The role of RBaK, PMS2, and GNA12 in the inheritance of familial hyperaldosteronism type II were studied. (PMID:18307725)
• Studies indicate that data on the regulatory functions of the KRAB-ZFP in embryonic development and tumorgenesis will benefit the understanding of biological roles of KRAB-ZFP in different physiological and pathological states. (PMID:20466629)
• A genome-wide association study for highly sensitive cardiac troponin T levels identified a novel genetic variation near a RBAK-ZNF890P locus in the Japanese general population. (PMID:33321125)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rbak	ENSMUSG00000061898
rattus_norvegicus	Rbak	ENSRNOG00000001099

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

RB-associated KRAB zinc finger protein — Q9NYW8 (reviewed: Q9NYW8)

Alternative names: RB-associated KRAB repressor, Zinc finger protein 769

All UniProt accessions (1): Q9NYW8

UniProt curated annotations — full annotation on UniProt →

Function. May repress E2F-dependent transcription. May promote AR-dependent transcription.

Subunit / interactions. Interacts with AR and RB1. May also interact with other nuclear hormone receptors such as NR3C1/GR.

Subcellular location. Nucleus.

Tissue specificity. Expressed in bone, brain, heart, kidney, liver, lung, pancreas and placenta.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NYW8-1	1	yes
Q9NYW8-2	2

RefSeq proteins (2): NP_001191385, NP_066986* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (30 total): zinc finger region 16, cross-link 6, region of interest 2, splice variant 2, chain 1, domain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NYW8-F1	66.35	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 97, 259, 315, 357, 534, 537

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 106 (showing top): RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, AAGCCAT_MIR135A_MIR135B, chr7p22, AGGAGTG_MIR483, ACATATC_MIR190, ZHANG_BREAST_CANCER_PROGENITORS_UP, MARIADASON_REGULATED_BY_HISTONE_ACETYLATION_DN, MODULE_69, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, WAKABAYASHI_ADIPOGENESIS_PPARG_BOUND_8D, ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP

GO Biological Process (3): regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (5): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
regulation of DNA-templated transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of gene expression	1
regulation of RNA biosynthetic process	1
transcription by RNA polymerase II	1
negative regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

796 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RBAK	RB1	P06400	662
RBAK	SLCO6A1	Q86UG4	512
RBAK	TAFA5	Q7Z5A7	455
RBAK	PRR22	Q8IZ63	370
RBAK	ARMC7	Q9H6L4	365
RBAK	C5orf24	Q7Z6I8	323
RBAK	ZFYVE26	Q68DK2	322
RBAK	POMZP3	Q6PJE2	321
RBAK	ANKRD13C	Q8N6S4	307
RBAK	GPR137C	Q8N3F9	304
RBAK	UPF3B	Q9BZI7	303
RBAK	ZCCHC10	Q8TBK6	294
RBAK	MAGED4B	Q96JG8	290
RBAK	SPATA20	Q8TB22	272
RBAK	POM121C	A8CG34	271

IntAct

116 interactions, top by confidence:

A	B	Type	Score
NEK6	RBAK	psi-mi:“MI:0915”(physical association)	0.560
TSGA10	RBAK	psi-mi:“MI:0915”(physical association)	0.560
TXK	RBAK	psi-mi:“MI:0915”(physical association)	0.560
BYSL	RBAK	psi-mi:“MI:0915”(physical association)	0.560
GAS8	RBAK	psi-mi:“MI:0915”(physical association)	0.560
CIB3	RBAK	psi-mi:“MI:0915”(physical association)	0.560
RBAK	TCAF1	psi-mi:“MI:0915”(physical association)	0.560
AQP1	RBAK	psi-mi:“MI:0915”(physical association)	0.560
ZNF648	RBAK	psi-mi:“MI:0915”(physical association)	0.560
CRACR2A	RBAK	psi-mi:“MI:0915”(physical association)	0.560
RBAK	ZNF330	psi-mi:“MI:0915”(physical association)	0.560
EIF1AD	RBAK	psi-mi:“MI:0915”(physical association)	0.560
LMO4	RBAK	psi-mi:“MI:0915”(physical association)	0.560
MAGOHB	RBAK	psi-mi:“MI:0915”(physical association)	0.560
L3MBTL2	RBAK	psi-mi:“MI:0915”(physical association)	0.560
TNS2	RBAK	psi-mi:“MI:0915”(physical association)	0.560
CARD9	RBAK	psi-mi:“MI:0915”(physical association)	0.560
ZNF121	RBAK	psi-mi:“MI:0915”(physical association)	0.560
EFEMP2	RBAK	psi-mi:“MI:0915”(physical association)	0.560
TRIM41	RBAK	psi-mi:“MI:0915”(physical association)	0.560
PRPF31	RBAK	psi-mi:“MI:0915”(physical association)	0.560
FGF12	RBAK	psi-mi:“MI:0915”(physical association)	0.560
RBAK	SLC25A10	psi-mi:“MI:0915”(physical association)	0.560
SCNM1	RBAK	psi-mi:“MI:0915”(physical association)	0.560
LNX1	RBAK	psi-mi:“MI:0915”(physical association)	0.560
PRKG1	RBAK	psi-mi:“MI:0915”(physical association)	0.560
MECP2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
ZNF169	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF324B	ZNF316	psi-mi:“MI:0914”(association)	0.530
ZNF707	ZNF316	psi-mi:“MI:0914”(association)	0.530

BioGRID (72): RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK (Affinity Capture-MS), RBAK-RBAKDN (Affinity Capture-RNA), RBAK (Affinity Capture-MS), RBAK (Positive Genetic), RBAK (Synthetic Lethality), RBAK (Two-hybrid), RBAK (Two-hybrid), RBAK (Two-hybrid)

ESM2 similar proteins: A2VDP4, A6NHJ4, O94892, P0CJ79, P17014, P17021, P17025, P17032, P17035, P18733, P51508, P51814, Q06730, Q06732, Q09FC8, Q0VGE8, Q14586, Q32M78, Q3MIS6, Q5JVG2, Q5R4K8, Q5R9S5, Q5RBQ3, Q5RCJ2, Q5RER9, Q5TYW1, Q5VIY5, Q6P560, Q6PDB4, Q6ZMW2, Q6ZN06, Q6ZNA1, Q76KX8, Q7L2R6, Q86Y25, Q8N184, Q8N823, Q8N883, Q8N8J6, Q8NEP9

Diamond homologs: A0JPL0, A2VDP4, A6QLU5, A6QPT6, A8MQ14, A8MUZ8, A8MWA4, B1APH4, B2RXC5, E9PYI1, E9Q8G5, O75290, O94892, P08042, P0CH99, P0CI00, P17014, P17025, P17030, P17031, P17032, P17098, P21506, P51508, P51523, P51786, P51814, P52736, P52738, Q02525, Q03923, Q03936, Q06730, Q06732, Q0VCB0, Q13401, Q14587, Q16587, Q2M218, Q2M3X9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

95 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	87
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
548976	GRCh37/hg19 7p22.1(chr7:4644965-5436368)x3	Likely pathogenic

SpliceAI

1222 predictions. Top by Δscore:

Variant	Effect	Δscore
7:5057382:G:T	donor_gain	1.0000
7:5057418:GTGG:G	donor_gain	1.0000
7:5045956:G:GT	donor_gain	0.9900
7:5046392:GAAGG:G	donor_gain	0.9900
7:5046395:GG:G	donor_gain	0.9900
7:5046396:GG:G	donor_gain	0.9900
7:5048089:CAGGT:C	donor_loss	0.9900
7:5048090:AGG:A	donor_loss	0.9900
7:5048091:GGT:G	donor_loss	0.9900
7:5048093:T:G	donor_loss	0.9900
7:5057370:A:G	donor_gain	0.9900
7:5057381:G:GT	donor_gain	0.9900
7:5057382:G:GT	donor_gain	0.9900
7:5057680:ACAGG:A	acceptor_loss	0.9900
7:5057681:CAGG:C	acceptor_loss	0.9900
7:5057682:A:AG	acceptor_gain	0.9900
7:5057682:A:C	acceptor_loss	0.9900
7:5057682:A:T	acceptor_loss	0.9900
7:5057682:AG:A	acceptor_gain	0.9900
7:5057683:G:GA	acceptor_loss	0.9900
7:5057683:G:GC	acceptor_loss	0.9900
7:5057683:G:GG	acceptor_gain	0.9900
7:5057683:GG:G	acceptor_gain	0.9900
7:5057683:GGAT:G	acceptor_gain	0.9900
7:5057777:CAGG:C	donor_loss	0.9900
7:5057777:CAGGT:C	donor_loss	0.9900
7:5057779:GGTA:G	donor_loss	0.9900
7:5057781:T:A	donor_loss	0.9900
7:5063693:A:AG	acceptor_gain	0.9900
7:5063694:G:GG	acceptor_gain	0.9900

AlphaMissense

4777 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:5065285:T:C	L610P	1.000
7:5065300:G:C	R615P	1.000
7:5065350:T:C	F632L	1.000
7:5065352:C:A	F632L	1.000
7:5065352:C:G	F632L	1.000
7:5065369:T:C	L638P	1.000
7:5065434:T:C	F660L	1.000
7:5065436:T:A	F660L	1.000
7:5065436:T:G	F660L	1.000
7:5065453:T:C	L666P	1.000
7:5064432:T:C	F326L	0.999
7:5064434:T:A	F326L	0.999
7:5064434:T:G	F326L	0.999
7:5064516:T:C	F354L	0.999
7:5064518:C:A	F354L	0.999
7:5064518:C:G	F354L	0.999
7:5064535:T:C	L360P	0.999
7:5064600:T:C	F382L	0.999
7:5064602:C:A	F382L	0.999
7:5064602:C:G	F382L	0.999
7:5064787:T:C	L444P	0.999
7:5065182:T:C	F576L	0.999
7:5065184:T:A	F576L	0.999
7:5065184:T:G	F576L	0.999
7:5065209:C:G	H585D	0.999
7:5065211:T:A	H585Q	0.999
7:5065211:T:G	H585Q	0.999
7:5065266:T:C	F604L	0.999
7:5065268:C:A	F604L	0.999
7:5065268:C:G	F604L	0.999

dbSNP variants (sampled 300 via entrez): RS1000160919 (7:5052884 C>A,T), RS1000215845 (7:5055794 G>C,T), RS1000312755 (7:5062396 G>C), RS1000367107 (7:5047179 C>T), RS1000434667 (7:5057904 T>A,G), RS1000439611 (7:5048371 A>C), RS1000556122 (7:5067615 C>T), RS1000824166 (7:5057019 A>G), RS1000874391 (7:5061915 A>T), RS1000889929 (7:5058146 C>G), RS1001161061 (7:5066413 A>C,G,T), RS1001163073 (7:5053950 T>C), RS1001495148 (7:5059280 T>C), RS1001525881 (7:5062733 C>A,G,T), RS1001737566 (7:5069819 T>C)

Disease associations

OMIM: gene MIM:608191 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression	4
trichostatin A	affects cotreatment, decreases expression	3
methylmercuric chloride	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
geldanamycin	increases expression	1
triphenyl phosphate	affects expression	1
quercitrin	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
pentanal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
MT19c compound	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Air Pollutants	increases abundance, decreases expression	1
Coal	decreases expression, increases abundance	1
Doxorubicin	affects expression	1
Drugs, Chinese Herbal	increases expression	1
Endosulfan	decreases expression	1
Formaldehyde	decreases expression	1
Mercuric Chloride	decreases expression	1
Naphthoquinones	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XV76	HEK293 eGFP-RBAK	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer